.jpeg)
The anti-tumor effect of Amivantamab
Amivantamab (Amivantamab) is a bispecific antibody that binds to the extracellular domains of EGFR and MET. In in vitro and in vivo studies, evantumumab was able to disrupt EGFR and methionine signaling functions by blocking ligand binding, and was able to degrade EGFR and methionine in an exon 20 insertion mutation model. The presence of EGFR and MET on the surface of tumor cells also allows these cells to be targeted for destruction by immune effector cells (such as natural killer cells and macrophages) through antibody-dependent cytotoxicity (ADCC) and trogocytosis mechanisms, respectively.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
